InflaRx N.V. IFRX 深 沪
等待开盘 02-17 09:30:00 美东时间
0.8527
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.8527
- 总市值 3.77万
- 52周最高 1.94
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.7113
- 委 比 0.00%
- 总股本 4.42万
- 历史最高 53.10
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.7113
- 每 手 1
- 风险率 0.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多InflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway
InflaRx outlines restructuring plans, workforce cuts, and reduced Gohibic spending to extend cash runway and focus development efforts on izicopan through mid-2027.
01-09 01:22
InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder
InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.
01-05 20:08
Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Shares of Viasat Inc (NASDAQ:VSAT) rose sharply in pre-market trading after the...
2025-11-10 17:51
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
InflaRx stops Phase 3 trial for vilobelimab in pyoderma gangrenosum due to futility, focusing on INF904 while maintaining GOHIBIC for COVID-19 treatment.
2025-05-28 05:30
InflaRx to Participate in Upcoming Investor Conferences
<p>InflaRx N.V. announced participation in multiple investor conferences in June and July 2025, including Jefferies Global Healthcare Conference, Oppenheimer Innovators in I&I Summit, and Leerink Partners Therapeutics Forum, to discuss its anti-inflammatory therapeutics targeting the complement system.</p>
2025-05-22 11:30
HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target
HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.
2024-09-26 01:34
